Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 14/20 | 0.55 |
| ▸ | NPM1 | P06748 | 3/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497163 | 0.88 | LCK (0.55) | LCKNPM1ALKBTKGABRA1 | |
| SCHEMBL2466070 | 0.84 | BTK (0.49) | LCKBTKGABRA1GABRA5 | |
| SCHEMBL31040869 | 0.81 | LCK (0.49) | LCKNPM1ALKBTKGABRA1 | |
| SCHEMBL7969599 | 0.78 | LCK (0.58) | LCKNPM1ALKBTKGABRA1 | |
| SCHEMBL7981080 | 0.77 | LCK (0.58) | LCK | |
| SCHEMBL31136593 | 0.76 | LCK (0.42) | LCKBTKLYN | |
| SCHEMBL7969710 | 0.76 | LCK (0.65) | LCKBTK | |
| SCHEMBL7984212 | 0.75 | NCOA3 (0.47) | BTK | |
| SCHEMBL31137424 | 0.75 | LCK (0.60) | LCKBTKLYN | |
| SCHEMBL4038017 | 0.74 | BTK (0.41) | LCKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-05-07 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4592289-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12173002-B2 | PRMT5 inhibitors and methods of use | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | LCK 1279/4885NPM1 279/4885ALK 2782/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | LCK 1551/4885NPM1 630/4885ALK 3947/4885 |
| US-12173002-B2 | PRMT5 inhibitors and methods of use | PRMT5, PRMT1, PRMT7 | LCK 1443/4885NPM1 194/4885ALK 3130/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | LCK 1551/4885NPM1 630/4885ALK 3947/4885 |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT7 | LCK 1052/4885NPM1 545/4885ALK 2917/4885 |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT1, PRMT5, PRMT6 | LCK 977/4885NPM1 268/4885ALK 3546/4885 |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT3 | LCK 1157/4885NPM1 208/4885ALK 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.